Clinical Review 139 - Endometrial cancer: Hormonal factors, the perimenopausal "window of risk," and isoflavones

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 1, 2002, Pages 3-15

  Hale, G E ^a,c   Hughes, C L ^a,b   Cline, J M ^b,c,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b IQVIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ISOFLAVONE DERIVATIVE; KI 67 ANTIGEN; PROGESTERONE;

CANCER PREVENTION; CANCER RISK; DIABETES MELLITUS; ENDOMETRIUM CANCER; HORMONAL REGULATION; HUMAN; LIFESTYLE; MENOPAUSE; MENSTRUAL CYCLE; PRIORITY JOURNAL; REVIEW; AGE; BLOOD; CLIMACTERIUM; DIET; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; EXERCISE; FEMALE; HORMONE SUBSTITUTION; LONGITUDINAL STUDY; METABOLISM; OBESITY; RISK FACTOR; URINE;

AGE FACTORS; CLIMACTERIC; DIABETES COMPLICATIONS; DIET; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ESTROGENS; EXERCISE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; ISOFLAVONES; LONGITUDINAL STUDIES; OBESITY; PROGESTERONE; RISK FACTORS;

EID: 0036150064     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.87.1.3     Document Type: Review

References (217)

1. Association of soy and fiber consumption with the risk of endometrial cancer
2. Normal variation in the length of the follicular phase of the menstrual cycle: Effect of chronological age
3. The hypothalamic-hypophyseal-ovarian axis and the menstrual cycle
4. Induction of the midcycle gonadotrophin surge by ovarian steroids in women: A critical evaluation
5. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women
6. The corpus luteum: Determinants of progesterone secretion in the normal menstrual cycle
7. The diagnosis of luteal phase deficiency: A critical review
8. Normal variation in the length of the the luteal phase of the menstrual cycle: Identification of the short luteal phase
9. Corpus luteum insufficiency induced by a rapid gonadotropin-releasing hormone-induced gonadotropin secretion pattern in the follicular phase
10. Luteal phase deficiency: Abnormal gonadotropin and progesterone secretion patterns
11. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion
12. Hormonal profile of the cycle in 68 normally menstruating women
13. Interpretation of single progesterone measurements in diagnosis of anovulation and defective luteal phase: Observations on analysis of the normal range
14. Clinical evaluation of luteal function
15. Steroid and gonadotrophin levels in women during the peri-menopausal years
16. Ovarian-pituitary hormone interactions during the perimenopause
17. Preliminary observations on urinary oestrogens excretion in certain gynaecological diseases
18. Hormonal regulation of estrogen and progestin receptors in decidual cells
19. Progestin induced down regulation of nuclear estrogen receptor in uterine decidual cells: Analysis of receptor synthesis and turnover by the the density-shift method
20. Induction of human endometrial estradiol dehydrogenase by progestins
21. Localization of estradiol 17-β dehydrogenase in the human endometrium
22. The role of estradiol dehydrogenase in mediating progestin effects on endometrium from postmenopausal women receiving estrogens and progestins
23. Characterization of uterine eptithelium apoptotic cell death kinetics and regulation by progesterone
24. The behavior of endometrial hyperplasia: A prospective study
25. The behavior of endometrial hyperplasia: A long term study of "untreated" hyperplasia in 170 patients
26. Endometrial hyperplasia in relation to genital function
27. Endometrial cystic glandular hyperplasia in adolescent girls
28. Endocrinologic features of oligomennorrhea in adolescent girls
29. Polycystic ovary syndrome in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens and insulin
30. The dose-effect relationship between unopposed estrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk
31. Proilferation kinetics of human endometrium during the normal menstrual cycle
32. Clinical application of morphologic and immunocytochemical assessments of cell proliferation
33. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
34. Cellular localization of c-Jun messender RNA and protein and their relation to proliferation marker Ki-67 in the human endometrium
35. The distribution of endometrial leukocytes and their proliferation markers in trimegesterone-treated postmenopausal women compared to the endometrium of the natural cycle: A dose ranging study
36. Proliferative activity of the endometrium throughout the menstrual cycle in infertile women with and without endometriosis
37. Immunocytochemical assays in human endometrial carcinomas: A multiparametric computerized analysis and comparison with non-malignant changes
38. Steroid receptors and proliferative activity in non-neoplastic endometria
39. Apoptosis and Ki-67 expression in adenomyotic lesions and in the corresponding eutopic endometrium
40. Apoptosis, proliferation and sex hormone Receptors in supoerficial parts of the human endometrium at the end of the secretory phase
41. Ki-67 Immunostaining of endometrial biopsies with special reference to hormone replacemnt therapy
42. Expression of steroid receptors, Ki-67 and epidermal growth factor receptor in Tamoxifen-treated endometrium
43. The Ki-67 protein: From the known to the unknown
44. Progestin-mediated changes in progesterone receptor forms in the normal human endometrium
45. Two distinct estrogen regulated promotors generate the transcripts of two functionally different human progesterone forms A and B
46. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium
47. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
48. Postmenopausal unopposed estrogens: Characteristics of use in relation to the risk of endometrial carcinoma
49. Risk of endometrial cancer following estrogen replacement with and without progestins
50. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
51. Pharmacokinetic and pharmacologic variation between different estrogen products
52. Structure-function relationships and metabolism of estrogens and progesterones
53. Low-dose esterified estrogen therapy
54. Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women
55. Bone loss in elderly women prevented by ultra-low doses of parenteral 17 β-estradiol
56. Oestradiol-releasing vaginal ring for treatment of urogenital atrophy
57. Transvaginal sonography of the internal genital organs in postmenopausal women on low-dose estrogen treatment
58. Associations between low levels of estradiol, bone density and fractures among elderly women: The study of osteoporotic fractures
59. Endogenous hormones and the risk of hip and vertabral fractures among elderly women: Study of Osteoporotic Fractures Research Group
60. Risk of endometrial cancer after treatment with estrogens alone or in conjugation with progestagens: Results of a prospective study
61. Progestagen supplementation of exogenous estrogens and risk of endometrial cancer
62. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
63. Morphometric, immunohistological and three dimensional evaluation of the endometrium of menopausal women treated by estrogen and Crinone, a new slow-release vaginal progesterone
64. Biochemical and histological effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women
65. Endometrial safety of continuous combined-hormone replacement therapy with 17 β-oestradiol (1 or 2 mg) and dydrogesterone
66. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women
67. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes
68. The epidemiology of endometrial cancer in young women
69. Endometrial cancer in young women taking oral contraceptive agents
70. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer
71. Estrogen-progestin replacement therapy and endometrial cancer
72. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
73. Effects of hormonal replacement therapy on endometrial histology in postmenopausal women
74. Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer
75. A prospective 1 year study of estroegen and progestin in postmenopausal women: The effects on the endometrium
76. Strategies to reduce the incidence of endometrial cancer in postmenopausal women
77. Hormonal chemoprevention of cancer in women
78. Endometrial cancer after combined hormone replacement therapy
79. Progestin regulation of cellular proliferation
80. A case-control study of cancer of the endometrium
81. The epidemiology of endometrial cancer
82. Nutrition and endometrial cancer
83. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer
84. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: Early findings of the Iowa Women's Health Study
85. Adipose tissue as a source of hormones
86. Androgen-estrogen metabolism in women with upper versus lower body obesity
87. Serum sex-hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial cancer
88. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status
89. Serum 17 β-estradiol and estrone levels in postmenopausal women with wnd without endometrial cancer
90. Free estradiol in postmenopausal women with and without endometrial cancer
91. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer
92. Serum concentrations of FSH, oestradiol, oestrone and androstenedione in normal and obese women
93. Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma
94. Abnormal sex steroid secretion and binding in massively obese women
95. Plasma oestrone, oestradiol and androstenedione levels in postmenopausal women: Relation to body weight and height
96. Sex hormone concentrations in postmenopausal women: Relation to obesity, fat mass, age and years postmenopause
97. Exercise, occupational activity and risk of endometrial cancer
98. Endometrial cancer, obesity, and body fat distribution
99. Early-age body size, adult weight gain and endometrial cancer risk
100. Body mass at different ages and subsequent endometrial cancer risk
101. Adenocarcinoma of the endometrium in women 40 years of age or younger
102. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding
103. Endometrial carcinoma in women under 40 years of age
104. Profile of women 45 years of age and younger with endometrial cancer
105. Elevations in unbound serum estradiol as a possible machanism for inappropriate gonadotropin secretion in women with PCO
106. Re: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status
107. Relationship of obesity to blood estrogens
108. Relationship between sex hormones and serum lipoprotein and lipoproten A concentrations in obese premenopausal women
109. Sex steroid, gonadotrophin, cortisol and prolactin levels in healthy massively obese women: Correlation with abdominal fat cell size and weight reduction
110. Racial differences in sex hormone levels in women approaching the transition to menopause
111. Predictors of ovarian steroid secretion in reproductive-age women
112. The role of estrogens and progestins in the epidemiology and prevention of breast cancer
113. Influence of body weight on estradiol metabolism in young women
114. Tissue specificity: The clinical importance of steroid metabolites in hormone replacement therapy
115. Nuclear binding and retention of the receptor estrogen complex: Relation to the agonistic and antagonistic properties of estriol
116. The relation of obesity to menstrual disturbances
117. The association of girth measurements with disease in 32,856 women
118. Endometrial cancer in young women
119. Reproductive, menstrual and medical risk factors for endometrial cancer: Results from a case-control study
120. Differences in circulating concentrations of total, free, bound leptin relate to gender and body composition in adult humans
121. Leptin inhibits gonadotrophin-stimulated granulosa cell progesterone production by antagonizing insulin action
122. Ovarian action of leptin: Effects on insulin-like growth factor-1-stimulated function of granulosa and thecal cells
123. Leptin modulates the glucocorticoid-induced ovarian steroidogenesis
124. The in vivo and in vitro effect of exogenous leptin on ovulation in the rat
125. Body size in different periods of life, diabetes mellitus, hypertension and risk of postmenopausal endometrial cancer
126. A case control study of diabetes mellitus and endometrial cancer risk
127. Constitutional stigmas associated with endometrial carcinoma
128. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: Comparison of endometrial cancer patients with healthy controls
129. Diabetes, body size and risk of endometrial cancer
130. Carbohydrate metabolism in patients with endometrial cancer
131. Hyperinsulinemia and stromal luteinization in the ovaries of postmenopausal women with endometrial cancer
132. Insulin and endometrial cancer
133. Suppressed expression of insulin-like growth factor binding protein-2 mRNA in the endometrium: A molecular mechanism associating endometrial cancer with its risk factors
134. Specific binding sites for insulin and insulin-like growth factor I in human endometrial cancer
135. Uterine insulin-like growth factor-1: Regulation of expression and its role in estrogen-induced uterine proliferation
136. Insulin-like growth factors and their binding proteins in benign and malignant uterine diseases
137. Growth factors and steroid hormone action in endometrial cancer
138. Decreased progesterone binding and attenuated progesterone action in cultured human breast cancer cells treated with epidermal growth factor
139. Physical exercise: A pillar for cancer
140. Does physical activity reduce risk of estrogen-dependent cancer in women
141. Lifestyle and endometrial cancer risk: A cohort from the Swedish Twin Registry
142. Risk for endometrial cancer in relation to occupational physical activity: A nationwide cohort study in Sweden
143. Past and present physical activity and endometrial cancer risk
144. Physical activity and risk of endometrial cancer
145. The relationship of exercise and anovulatory cycles in female athletes: Hormonal and physical characteristics
146. Induction of menstrual disorders by strenuous exercise in untrained women
147. Caloric intake, stress and menstrual function in athletes
148. Lack of effect of initiation of exercise training on incidence of anovulation
149. Luteal phase deficiency: Characterization of reproductive hormones over the menstrual cycle
150. Risk factors for endometrial cancer at different ages
151. Role of diet in endometrial cancer patients
152. A population based case-contol study of dietary factors and endometrial cancer in Shanghai, People's Republic of China
153. Diet and endometrial cancer: A case-control study
154. Dietary associations in a case-control study of endometrial cancer
155. Dietary factors and the risk of endometrial cancer
156. Diet, body size, physical activity and the risk of endometrial cancer
157. Dietary intake of energy and animal foods and endometrial cancer incidence: The Iowa Women's Study
158. Diet and reproductive hormones: A study of vegetarian and non-vegetarian postmenopausal women
159. The relationship between estrogen levels and diets of Caucasian American and Oriental women
160. Nutrient intake and hormonal status of premenopausal vegetarian Seventh Day Adventists and premenopausal non-vegetarians
161. Dietary fat reduction and plasme estradiol concentration in healthy postmenopausal women
162. Effect of a low-fat intakes on the hormonal milieu of premenopausal women
163. Diet and female sex hormone concentrations: An intervention study for the type of fat consumed
164. Diet and urine estrogens among postmenopausal women
165. Alcohol and dietary factors in relation to serum hormone concentrations in women at climacteric
166. The effect of a low fat diet on estrogen metabolism
167. Endometrial hyperplasia and endometrial cancer
168. Comparative epidemiology of cancer between the United States and Japan: A second look
169. Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women
170. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women
171. Modest hormonal effects of soy isoflavones in postmenopausal women
172. Short-term effects of phytoestrogen-rich diet on postmenopausal women
173. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women
174. A specific breeding problem of sheep on subterranean clover pastures in Western Australia
175. The interaction in the immature mouse of potent estrogens with coumestrol, genistein and other utero-trophic compounds of low potency
176. The oestrogenic activity of and metabolism of certain isoflavones in sheep
177. The distribution of oestrogenic isoflavones in the genus Trifolium
178. In vitro bioassays of non-steroidal phytoestrogens
179. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
180. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β and β
181. The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: Physiology of delivery modifies estrogenic activity
182. Inhibition of human aromatase by mammalian lignans and isoflavanoid phytoestrogens
183. Genistein: A specific inhibitor of tyrosine-specific protein kinase
184. Inhibition of 5-α reductase in genital skin fibroblasts and prostate tissue
185. Estrogen speclfic 17β-hydroxysteroid oxidoreductase type I (EC. 1.1.1.62) as a possible target for the action of phytoestrogens
186. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein
187. Genistein is an effective stimulator of SHGB production in hepatocarcinoma human liver cells and supresses proliferation of these cells in culture
188. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women
189. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study
190. Clinical effects of a standardized soy extract in postmenopausal women: A pilot study
191. A double blind placebo controlled trial on the effect of an isoflavone, P-07 on the endometrium
192. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques
193. Effects of dietary soybean estrogens on the reproductive tract in female rats
194. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats
195. Protein tyrosine kinase activity of lavendustin A and the phytoestrogen genistein on progesterone synthesis in culture rat ovarian cells
196. Perimenopause: The complex endocrinology of the menopausal transition
197. Urinary excretion of hormones during the climacteric
198. Prospectively measured levels of serum follicle-stimulating hormone, estradiol and dimeric inhibins during the menopausal transition in a population-based cohort of women
199. Characterization of reproductive hormonal dynamics in the perimenopause
200. Pituitary ovarian relationships preceding the menopause: A cross-sectional study serum follicle stimulating hormone and luteinizing hormone, prolactin, estradio and progesterone levels
201. Hormone profiles and psychological symptoms in perimenopausal women
202. Age effects on follicle-stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women
203. Return of fertility after childbirth and during lactation and changes in the climacteric
204. A longitudinal study of the perimenopausal transition: Altered profiles of steroid and pituitary hormones, SHBG and bone mineral density
205. Incidence of ovulatory cycles in women approaching the menopause
206. Menstrual cycle and exposure to estrogens unopposed by progesterone: Relevance to studies on breast cancer incidence
207. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone
208. Evaluating the effect of age on endometrial responsiveness to hormone replacement therapy: A histologic ultrasonographic and tissue receptor analysis
209. Morphological and functional aspects of the endometrium of asymptomatic post-menopausal women: Does the endometrium really age?
210. Role of growth factors in the human endometrium during aging
211. Age-related expression of PEDF/EPC-1 in human endometrial stromal fibroblasts: Implications for interactive senescence
212. Immunohistochemical analysis of distribution of estrogen and progesterone receptors in the postmenoapausal endometrium
213. Gatekeeper for endometrium: The PTEN tunor suppressor gene
214. Molecular identification of latent precancers in histologically normal endometrium
215. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
216. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasia
217. Effects of age on endometrial carcinogenesis induced by concurrent oral administration of ethylenethiourea and sodium nitrite in mice